Warning Letter to Burzynski Research Institute, Ref. 13-HFD-45-11-05 (2013)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Scientific Investigations · December 3, 2013

U.S. Food et al., 2013-12-03: FDA warning letter to Burzynski Research Institute as trial sponsor, documenting that 9 of 27 reviewed subjects had response categories misclassified, that some 'complete responses' did not meet protocol criteria, and that informed consent was not obtained in accordance with regulations.

BRI monitoring failed to identify and correct the clinical investigator's incorrect classification of therapeutic responses for 9 of the 27 subjects whose therapeutic response classifications were reviewed during the inspection.

HTML letter, unpaginated

U.S. Food et al., 2013-12-03: FDA warning letter to Burzynski Research Institute as trial sponsor, documenting that 9 of 27 reviewed subjects had response categories misclassified, that some 'complete responses' did not meet protocol criteria, and that informed consent was not obtained in accordance with regulations. This is the document that most directly bears on 'remarkable success rates': the response classifications underlying published antineoplaston results were audited and found wrong in one third of reviewed cases, several because patients were on corticosteroids or because responses were not maintained four weeks. BRI disputed the findings and proposed amending the protocol definitions rather than the assessments. No funder or conflicts (regulatory record). Study type: regulatory record.